bpmc_8K (ATA press release and presentation)(October 2018)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): October 6, 2018

 


 

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

 


 

Delaware

001-37359

26-3632015

(State or other jurisdiction
of incorporation)

(Commission File Number)

(I.R.S. Employer
Identification No.)

 

 

45  Sidney Street
Cambridge, Massachusetts

02139

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (617) 374-7580

 

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 7.01Regulation FD Disclosure.

 

On October 6, 2018, Blueprint Medicines Corporation issued a press release announcing the presentation of updated data for RET-altered medullary thyroid cancer (“MTC”) patients and papillary thyroid cancer patients from its ongoing Phase 1 ARROW clinical trial evaluating BLU-667 for the treatment of RET-altered non-small cell lung cancer, MTC and other advanced solid tumors. The data were presented on Saturday, October 6, 2018 in an oral presentation at the 88th Annual Meeting of the American Thyroid Association (the “ATA Annual Meeting”) in Washington, D.C. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the presentation at the ATA Annual Meeting is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

 

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

    

Description

99.1

 

Press release issued by Blueprint Medicines Corporation on October 6, 2018

99.2

 

Presentation by Blueprint Medicines Corporation on October 6, 2018

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BLUEPRINT MEDICINES CORPORATION

 

 

 

 

Date: October 9, 2018

By:

/s/ Tracey L. McCain

 

 

Tracey L. McCain

 

 

Chief Legal Officer

 

 

3


bpmc_Ex99_1

Exhibit 99.1

Picture 1

 

Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers

 

90 percent of evaluable MTC and PTC patients had tumor reductions

62 percent response rate in MTC patients treated with 300 to 400 mg once daily for at least 24 weeks

Patients with longest treatment durations remain on therapy for more than 15 months

 

CAMBRIDGE, Mass., October 6, 2018 – Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the presentation of updated data from the ongoing Phase 1 ARROW clinical trial of BLU-667, an investigational precision therapy targeting RET alterations, including resistance mutations.  The new results showed that BLU-667 was highly active and well-tolerated in patients with advanced RET-altered medullary thyroid cancer (MTC) and papillary thyroid cancer (PTC), with increased activity observed with higher dose levels and longer treatment durations.  

 

The reported data showed 90 percent of evaluable patients with MTC and PTC had radiographic tumor reductions, regardless of RET alteration type or prior multi-kinase inhibitor (MKI) therapy.  In addition, the response rate was 62 percent in patients with MTC treated once daily (QD) with BLU-667 at doses of 300 to 400 mg for at least 24 weeks. In the MTC and PTC populations, all responders across dose levels and all patients treated at 400 mg QD remain on study.  Safety results were consistent with prior data, and the majority of adverse events (AEs) were Grade 1. These results were as of a data cutoff date of September 14, 2018 and were reported today in an oral presentation at The 88th Annual Meeting of the American Thyroid Association (ATA).

 

“Existing treatment of medullary and papillary thyroid cancer with multi-kinase inhibitors is limited by frequent dose modifications or interruptions due to off-target toxicities,  reducing the opportunity for a meaningful or sustained response,” said Andy Boral, M.D., Ph.D., Chief Medical Officer of Blueprint Medicines. “These new data showed selectively targeting RET alterations with BLU-667 was well-tolerated and enabled durable responses.  Importantly, response rates were high for patients with prolonged time on therapy at higher dose levels, demonstrating that potent and sustained target inhibition leads to improved patient outcomes. We believe these results begin to reveal the potential of BLU-667 to transform the care of patients with RET-altered thyroid cancer, and we look forward to seeing the data continue to mature as additional patients are treated at the recommended phase 2 dose for longer durations.”

 

Based on the encouraging data reported to date, Blueprint Medicines has expanded enrollment targets for the ARROW trial to further evaluate the safety and efficacy of BLU-667 in a broader patient population and, ultimately, to support potential registration.

 

Data Highlights from the Ongoing Phase 1 ARROW Clinical Trial

 

The data presented included all patients enrolled in the Phase 1 ARROW clinical trial as of May 9, 2018 and included follow-up on these patients through the data cutoff date of September 14, 2018. Of the 69 patients who had been treated with BLU-667 in the dose escalation and expansion portions of the trial, 42 had RET-altered thyroid cancer, including 37 with MTC and five with PTC. In the dose escalation 


 

 

portion, patients were treated at dose levels ranging from 30 mg to 600 mg QD or up to 300 mg twice daily.  In the expansion portion, patients were treated at the recommended phase 2 dose of 400 mg QD.

 

Clinical Activity Data

 

As of the data cutoff date, 35 patients with MTC and four patients with PTC were evaluable for response assessment by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Overall, 90 percent of MTC and PTC patients with measurable target lesions had radiographic tumor reductions.

 

In patients with MTC, response assessments showed increased clinical activity with higher dose levels and longer treatment durations. Across all evaluable MTC patients, the overall response rate (ORR) was 49 percent, including one patient with a confirmed complete response (CR) and 16 patients with a partial response (PR; two pending confirmation). In patients with MTC treated with 300 to 400 mg QD for at least 24 weeks, the response rate was 62 percent, including one patient with a confirmed CR and seven patients with a confirmed PR.

 

In patients with PTC, two of four evaluable patients had a  confirmed PR, and all evaluable patients with PTC had radiographic tumor shrinkage.

 

The data also showed encouraging evidence of durable activity. All patients with MTC and PTC who responded to BLU-667 remain on treatment as of the data cutoff date.  In addition, all patients treated at 400 mg QD are continuing on therapy.  Patients with the longest treatment durations remain on therapy for more than 15 months.

 

Anti-tumor activity was observed regardless of prior MKI therapy or RET alteration. Similar response rates were observed in MTC patients who were MKI-experienced (47 percent; 8/17 patients) and MKI-naïve (50 percent; 9/18 patients). In addition, clinical responses were observed in patients with common activating mutations in MTC (e.g., M918T) and fusion partners in PTC (e.g., NCO4A and CCDC6). A clinical response was also observed in the one evaluable MTC patient with a germline V804M gatekeeper mutation.

 

Safety Data

 

The reported data showed that across 69 patients, BLU-667 was well-tolerated as of the data cutoff date. Most AEs were Grade 1, and only two patients discontinued therapy due to a treatment-related AE (Grade 3 increased alanine aminotransferase in a patient with liver metastases and Grade 2 pneumonitis). Treatment-emergent AEs (regardless of relationship to BLU-667)  reported by investigators (≥15 percent) most commonly were constipation (35 percent), increased aspartate aminotransferase (33 percent), anemia (30 percent), hypertension (30 percent), decreased white blood cell count (29 percent), diarrhea (28 percent), neutropenia (28 percent), increased alanine aminotransferase (25 percent), increased blood creatinine (23 percent), fatigue (19 percent) and headache (17 percent). Grade 3 or higher treatment-related AEs occurring in two or more patients included anemia, hypertension, decreased white blood cell count, diarrhea and neutropenia.

 

About the Phase 1 ARROW Clinical Trial of BLU-667

 

ARROW is a Phase 1 clinical trial designed to evaluate the safety, tolerability and efficacy of BLU-667 in multiple ascending doses in adults with RET-altered non-small cell lung cancer (NSCLC), MTC and other


 

 

advanced solid tumors. The trial consists of two parts: a dose escalation portion and an expansion portion. Enrollment in the dose escalation portion is complete, and the expansion portion has been initiated and is actively enrolling patients in six defined cohorts at the recommended phase 2 dose of 400 mg QD: (1) RET-altered NSCLC patients previously treated with an MKI, (2) RET-altered NSCLC patients who have not previously received any MKI treatment, (3) MTC patients previously treated with an MKI,  (4) MTC patients who have not previously received any MKI treatment, (5) patients with other RET-altered solid tumors and (6) RET-altered solid tumor patients with prior selective RET tyrosine kinase inhibitor. Trial objectives include assessing response, pharmacokinetics, pharmacodynamics and safety. The trial is designed to enroll approximately 190 patients across all six expansion cohorts, at multiple sites in the United States,  European Union and Asia.

 

Patients and physicians interested in the ARROW clinical trial can contact the Blueprint Medicines study director at arrow@blueprintmedicines.com or 1-617-714-6707. Additional details are available at www.arrowtrial.com or www.clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT03037385).

 

About RET-Altered Solid Tumors

 

RET activating fusions and mutations are a key disease driver in many cancer types, including NSCLC and MTC. RET fusions are implicated in approximately 1 to 2 percent of patients with NSCLC and approximately 10 percent of patients with PTC, while RET mutations are implicated in approximately 60 percent of patients with MTC. In addition, oncogenic RET alterations are observed at low frequencies in colorectal, breast, pancreatic and other cancers, and RET fusions have been observed in patients with treatment-resistant, EGFR-mutant NSCLC.

 

Currently, there are no approved therapies that selectively target RET-driven cancers, though there are several approved MKIs with RET activity being evaluated in clinical trials. Thus far, clinical activity attributable to RET inhibition has been uncertain for these inhibitors, likely due to insufficient inhibition of RET and off-target toxicities. There is a need for precision therapies that provide durable clinical benefit by selectively targeting RET alterations and resistance mutations.

 

About BLU-667

 

BLU-667 is an investigational, once-daily oral precision therapy specifically designed for highly potent and selective targeting of oncogenic RET fusions, mutations and resistance mutations. In preclinical studies, BLU-667 consistently demonstrated sub-nanomolar potency against the most common RET fusions, activating mutations and resistance mutations. In addition, BLU-667 demonstrated markedly improved selectivity for RET compared to approved MKIs, including more than 80-fold improved potency for RET versus VEGFR2. By suppressing primary and secondary mutants, BLU-667 has the potential to overcome and prevent the emergence of clinical resistance. This approach is expected to enable durable clinical responses across the range of RET alterations, with a favorable safety profile.

 

BLU-667 was discovered by Blueprint Medicine’s research team based on its proprietary compound library. The company is developing BLU-667 for the treatment of people with RET-altered NSCLC, MTC and other solid tumors. Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of BLU-667 and certain other drug candidates in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for BLU-667 in the rest of the world.

 


 

 

About Blueprint Medicines

 

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases. Blueprint Medicines is advancing multiple programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans and timelines for the clinical development of BLU-667; expectations regarding the potential benefits of BLU-667 in treating patients with RET-altered thyroid cancers, including patients with RET-altered MTC or PTC; expectations regarding the potential to treat patients at the recommended phase 2 dose for longer durations and Blueprint Medicines’ strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines’ drug candidates, including avapritinib, BLU-554, BLU-667 and BLU-782; Blueprint Medicines’ advancement of multiple early-stage efforts; Blueprint Medicines’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the preclinical and clinical results for Blueprint Medicines’ drug candidates, which may not support further development of such drug candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for its current and future drug candidates, including companion diagnostic tests for BLU-554 for FGFR4-driven hepatocellular carcinoma, avapritinib for PDGFRα D842V-driven gastrointestinal stromal tumors and advanced systemic mastocytosis and BLU-667 for RET-driven non-small cell lung cancer; the success of Blueprint Medicines’ current and future collaborations, including its cancer immunotherapy collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. and its collaboration with CStone Pharmaceuticals. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, as filed with the Securities and Exchange Commission (SEC) on August 1, 2018, and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

 


 

 

Investor Relations Contact

 

Kristin Hodous

617-714-6674

KHodous@blueprintmedicines.com 

 

Media Relations Contact

 

Andrew Law

617-844-8205

ALaw@blueprintmedicines.com 

 


bpmc_Ex99_2

Exhibit 99.2

 

 

 

New Microsoft Word Document_slide001.gif

Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study Mimi I. Hu, Matthew Taylor, Lori Wirth, Viola Zhu, Robert Doebele,  Dae Ho Lee, Ignacio Matos, Christina Baik, Marcia Brose, Giuseppe Curigliano, Gilberto de Lima Lopes, Dong-Wan Kim, Daniel Tan, Chia-Chi Lin, Michael Palmer, Meera Tugnait, Hui Zhang, Brenton Mar, Corinne Clifford, Beni Wolf, Elena Garralda, Sai-Hong Ignatius Ou,  Vivek Subbiah, Justin Gainor 1 NCT03037385 ©2018 Blueprint Medicines Corporation 88th Annual Meeting of the American Thyroid Association Washington, DC • October 6, 2018

 

 


 

New Microsoft Word Document_slide002.gif

I have the following financial relationships to disclose: Research support: Sanofi-Genzyme Consultant: Blueprint Medicines Corporation Advisory board: Loxo Oncology 2 Disclosures BLU-667 is an investigational agent discovered and currently in development by Blueprint Medicines Corporation (Blueprint Medicines)

 

 


 

 

 

Picture 17

Biochemical IC50 (nM) RET M918T Most common in MTC RET V804M Gatekeeper resistance in MTC CCDC6-RET Occurs in PTC VEGFR2 BLU-667 0.4 0.4 0.4 35 Cabozantinib 8 45 34 2 Vandetinib 7 3597 20 4 Sorafenib 23 32 ND 21 Lenvatinib 3 360 4 0.7 3 BLU-667 is designed to treat RET-altered cancers VEGFR, vascular endothelial growth factor receptor; IC50, half maximal inhibitory concentration; MTC, medullary thyroid cancer; CCDC6, coiled-coil domain containing 6; PTC, papillary thyroid cancer; ND, not determined. Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and the authors and Blueprint Medicines are not responsible for its content Hu et al. International Thyroid Oncology Group (ITOG) 2018 Subbiah et al. American Association for Cancer Research (AACR) 2018 (clinical trials plenary presentation) Subbiah et al. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discovery, July 2018 BLU-667 potently inhibits RET alterations and resistance mutants while sparing VEGFR2 PHASE 1, PART 1: PROOF OF CONCEPT RET-mutant MTC

 

 


 

 

 

Picture 16

4 ARROW trial: first-in-human study with BLU-667 MTD, maximum tolerated dose; RP2D, recommended Part 2 dose; BOIN, Bayesian optimal interval; MTC, medullary thyroid cancer; NSCLC, non–small cell lung cancer; QD, once daily; BID, twice daily; PO, orally; ORR, overall response rate; MKI, multikinase inhibitor; PTC, papillary thyroid cancer; TKI, tyrosine kinase inhibitor. NCT03037385 PART 1: Dose escalation – complete PART 2: Dose expansion – ongoing RET-altered NSCLC with no prior MKI RET-altered NSCLC with prior MKI MTC with prior MKI BOIN design Advanced MTC, NSCLC*, or other solid tumor* MTC with no prior MKI Other RET-altered solid tumors (including PTC) RET-altered solid tumors with prior selective RET TKI Part 1: 62 patients treated 53 treated at 30 – 600 mg QD 9 treated at 200 – 300 mg divided BID dosing *All NSCLC and other solid tumors were RET-altered in cohorts higher than 30 mg QD Objective: Determine MTD/RP2D Proof of concept Objective: Determine Overall Response Rate MTD/RP2D 400 mg PO daily Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide005.gif

5 Patient demographics and baseline characteristics ECOG, Eastern Cooperative Oncology Group; PS, performance status; MKI, multikinase inhibitor; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; NSCLC, non–small cell lung cancer; CCDC6, coiled-coil domain containing 6; NCOA4, nuclear receptor coactivator 4. Parameter Total (N=69) Age (years), median (range) 57 (19-85) Sex, male, n (%) 42 (61) ECOG, PS, n (%) 0 26 (38) 1-2 43 (62) Metastatic disease, n (%) 65 (94) Prior systemic therapy, n (%) 51 (74) Multikinase inhibitor 21 (30) Number of prior regimen, median (range) 1 (0-8) Tumor type, n (%) Medullary thyroid cancer 37 (54) RET fusion papillary thyroid cancer 5 (7) RET fusion non–small cell lung cancer 23 (33) RET fusion intrahepatic bile duct carcinoma 1 (1) RET mutation retroperitoneal paraganglioma 1 (1) Non-RET altered solid tumors 2 (3) > 1 RET Mutation (5%) MTC (N=37) RET M918T (70%) RET C634R/S/W (11%) Other RET (11%) RET Fusion PTC (N=5) NCOA4 (N=3) CCDC6 (N=2) RET V804M (3%) Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide006.gif

6 BLU-667 has profound activity in RET-altered thyroid cancer NCO4A, nuclear receptor coactivator 4; CCDC6, coiled-coil domain containing 6; M, prior MKI therapy; C, prior chemotherapy; O, other therapy; I, prior immunotherapy; PD, progressive disease; SD, stable disease; PR, partial response. Responses seen regardless of RET alteration, including RET V804M,* or prior treatment 90% of evaluable RET-altered thyroid cancer patients had tumor shrinkage Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide007.gif

7 Response rate in MTC patients increases with dose and duration of therapy #Evaluable patients at a specific week considers only post baseline assessments up to at that week of therapy (based on cycle start), or those that discontinued therapy or progressed prior to that. MTC, medullary thyroid cancer; QD, once daily; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors. Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018. Best response n, (%) Total All doses All cycles (N=35) 300/400 mg QD At 8 weeks (N=17) At 16 weeks (N=16) At 24+ weeks (N=13) ORR 17 (49) 6 (35) 9 (56) 8 (62) CR 1 (3) 1 (6) 1 (6) 1 (8) PR 16 (46) 5 (29) 8 (50) 7 (54) SD 18 (51) 10 (59) 7 (44) 5 (39) PD 0 (0) 0 (0) 0 (0) 0 (0) MTC Response Evaluable# Patients Pending confirmation: 3 PR 1 CR, 5 PR 2 PR 300/400 mg QD 60-200 mg QD Response rate N= N= 300/400 mg QD 60-200 mg QD 17 14 16 14 13 14 Follow up (weeks) 62% Response Rate at 24+ weeks in MTC at 300/400 mg QD 0% 10% 20% 30% 40% 50% 60% 70% 8 16 24+

 

 


 

New Microsoft Word Document_slide008.gif

8 High ORR in MTC patients treated with BLU-667 regardless of prior MKI Treatment MKI, multikinase inhibitor; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; RECIST, Response Evaluation Criteria in Solid Tumors. *2 PRs pending confirmation #Evaluable patients at all cycles include all dosed patients with RECIST target lesions with 1 or more post-baseline assessments or progressed or ended therapy for any reason. Best Response Total (n=35) n (%) No prior MKI (n=18) n (%) Prior MKI (n=17) n (%) ORR (CR+PR) 17 (49) 9 (50) 8 (47) CR 1 (3) 1 (6) - PR* 16 (46) 8 (44) 8 (47) SD 18 (51) 9 (50) 9 (53) MTC Response Evaluable# Patients Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide009.gif

9 BLU-667 shows durable responses in thyroid cancer patients Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018 PD, progressive disease. * Patients were allowed to continue on treatment following progressive disease if there was continued clinical benefit. Patients remain on treatment for more than 15 months Overall, 35 of 42 (83%) patients remain on treatment 14 of 14 (100%) treated at 400 mg QD remain on treatment 19 of 19 (100%) of responders remain on treatment Responses increase over time *

 

 


 

New Microsoft Word Document_slide010.gif

MTC, medullary thyroid cancer; CEA, carcinoembryonic antigen. *Tumor marker normalized. Significant declines in MTC tumor markers 10 23 of 28 (82%) decrease ≥50% Carcinoembryonic Antigen (CEA) * 34 of 37 (92%) decrease ≥50% Calcitonin * * * * * * * * * * * * * * * Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide011.gif

52-year-old male gastroenterologist with MTC (germline RET V804M gatekeeper mutation) with metastases to neck and mediastinal lymph nodes, lungs, liver and bone Progressive disease in liver on sunitinib (AE’s: anorexia, weight loss, diarrhea, hand/foot syndrome, fatigue) Initiated BLU-667 at 100 mg BID and escalated to 400 mg QD at C3D1 By C5D1, showed -41% (PR) reduction in liver metastases; gaining weight (BMI increased from 18.9 to 23.5), no diarrhea Remains on treatment in Cycle 7 with continued PR 11 BLU-667 demonstrates potent activity in germline RET V804M mutant MTC MTC, medullary thyroid cancer; BSL, baseline; PD, progressive disease; AE, adverse event; BID, twice daily; QD, once daily; PR, partial response; BMI, body mass index. Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide012.gif

23-year-old woman with PTC, sclerosing variant (CCDC6-RET fusion) who presented 6 years ago with symptomatic diffuse lung metastases requiring supplemental oxygen (O2) since diagnosis; treated with I-131 (total activity 351 mCi) with subsequent fibrosis Progressed on sorafenib and early this year on lenvatinib (increasing O2 needs, pleural effusions and intubated 3 times over 6 wks) Initiated BLU-667 at 400 mg once daily RECIST SD (no target lesion/non-target lymphangitic lung metastases) Symptomatic response: O2 weaned monthly to room air within 5 months, baseline BMI 14.8 steadily increased to 22.3 after 6 mos Remains on treatment at Cycle 8 and plans to start college and get her driver’s license this Fall 12 BLU-667 induced dramatic improvement in young PTC patient PTC, papillary thyroid cancer; BSL, baseline; CCDC6, coiled-coil domain containing 6; O2, oxygen; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; BMI, body mass index. Patient had non-measurable disease at baseline and is not represented on current waterfall plot. Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018 Baseline

 

 


 

New Microsoft Word Document_slide013.gif

Safety - BLU-667 is well tolerated AE, adverse event; ALT, alanine aminotransferase. *Discontinuations for related AEs: ↑ALT (gr3) and pneumonitis (gr2) All doses and patients, N=69 Treatment-emergent AEs (≥15% overall) Treatment-related AEs Adverse Event Any event n (%) Grade 1 Grade 2 Grade 3 Grade 4 Grade 3 Grade 4 Constipation 24 (35) 22 (32) 2 (3) - - - - Aspartate aminotransferase increased 23 (33) 20 (29) 3 (4) - - - - Anemia 21 (30) 8 (12) 7 (10) 6 (9) - 4 (6) - Hypertension 21 (30) 5 (7) 5 (7) 11 (16) - 6 (9) - White blood cell count decreased 20 (29) 7 (10) 10 (15) 3 (4) - 3 (4) - Diarrhea 19 (28) 11 (16) 3 (4) 5 (7) - 4 (6) - Neutropenia 19 (28) 5 (7) 5 (7) 6 (9) 3 (4) 5 (7) 2 (3) Alanine aminotransferase increased 17 (25) 16 (23) - 1 (1) - 1 (1) - Blood creatinine increased 16 (23) 15 (28) 1 (1) 0 - 0 - Fatigue 13 (19) 9 (13) 3 (4) 1 (1) - 1 (1) - Headache 12 (17) 9 (13) 2 (3) 1 (1) - 1 (1) - Most AEs were Grade 1 Only 2 discontinuations for related AEs* 13 Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide014.gif

BLU-667 has demonstrated: Responses across RET genotypes, which increase with dose and time on treatment Durable and high ORR of 62% at 300/400 mg QD in patients with MTC at 24+ weeks 100% of MTC patients treated at 400 mg daily remain on treatment ORR of ~50% in MTC patient regardless of prior MKI treatment Patients remain on treatment for more than 15 months 100% of responders remain on treatment BLU-667 is well tolerated at efficacious doses in MTC and PTC patients Results warrant further clinical development in MTC and PTC ARROW trial Part 2 dose expansion is open and enrolling globally in the United States, Europe, and Asia 14 Conclusions ORR, overall response rate; QD, once daily; MTC, medullary thyroid cancer; MKI, multikinase inhibitor; PTC, papillary thyroid cancer. Patients Enrolled as of 9 May 2018, Follow-up as of 14 Sep 2018

 

 


 

New Microsoft Word Document_slide015.gif

We thank the participating patients, their families, all study co-investigators, and research coordinators at the following institutions: 15 Acknowledgments The University of Texas MD Anderson Cancer Center, Houston, TX, United States The Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States Massachusetts General Hospital Cancer Center, Boston, MA, United States Chao Family Comprehensive Cancer Center University of California Irvine Medical Center, Irvine, CA, United States University of Colorado, Aurora, CO, United States University of Miami, Miami, FL, United States University of Washington, Seattle Cancer Care Alliance, Seattle, WA, United States Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States Asan Medical Center, Seoul, Republic of Korea Vall d’Hebron University Hospital, Barcelona, Spain University of Milano, Istituto Europeo di Oncologia, Milan, Italy Seoul National University Hospital, Seoul, Republic of Korea National Cancer Centre Singapore, Singapore, Singapore National Taiwan University Hospital, Taipei, Taiwan